Complications of influenza and benefits of vaccination.
Identifieur interne : 000681 ( Main/Exploration ); précédent : 000680; suivant : 000682Complications of influenza and benefits of vaccination.
Auteurs : K L Nichol [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 1999.
Descripteurs français
- KwdFr :
- Argentine (épidémiologie), Cardiopathies (étiologie), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (complications), Grippe humaine (mortalité), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Maladies du rein (étiologie), Maladies pulmonaires (étiologie), Manitoba (épidémiologie), Mâle (MeSH), Rhumatismes (étiologie), Royaume-Uni (épidémiologie), Sujet âgé (MeSH), Vaccins antigrippaux (usage thérapeutique), États-Unis (épidémiologie).
- MESH :
- mortalité : Grippe humaine.
- prévention et contrôle : Grippe humaine.
- usage thérapeutique : Grippe humaine, Vaccins antigrippaux.
- épidémiologie : Argentine, Espagne, Grippe humaine, Manitoba, Royaume-Uni, États-Unis.
- étiologie : Cardiopathies, Maladies du rein, Maladies pulmonaires, Rhumatismes.
- Femelle, Humains, Mâle, Sujet âgé.
English descriptors
- KwdEn :
- Aged (MeSH), Argentina (epidemiology), Female (MeSH), Heart Diseases (etiology), Humans (MeSH), Influenza Vaccines (therapeutic use), Influenza, Human (complications), Influenza, Human (epidemiology), Influenza, Human (mortality), Influenza, Human (prevention & control), Kidney Diseases (etiology), Lung Diseases (etiology), Male (MeSH), Manitoba (epidemiology), Rheumatic Diseases (etiology), Spain (epidemiology), United Kingdom (epidemiology), United States (epidemiology).
- MESH :
- chemical , therapeutic use : Influenza Vaccines.
- complications : Influenza, Human.
- epidemiology : Argentina, Influenza, Human, Manitoba, Spain, United Kingdom, United States.
- etiology : Heart Diseases, Kidney Diseases, Lung Diseases, Rheumatic Diseases.
- mortality : Influenza, Human.
- prevention & control : Influenza, Human.
- Aged, Female, Humans, Male.
Abstract
Uncertainty regarding the benefits of influenza vaccination may contribute to the underutilization of this vaccine. We have conducted serial cohort studies using the administrative data bases of a Twin Cities based managed care organization to assess the impact of disease and benefits of vaccination among the elderly. For the 6 seasons 1990-1991 through 1995-1996, there were more than 20,000 elderly members of the health plan included in each cohort. Data collected included information on baseline demographic and health characteristics, vaccination status and outcomes (hospitalizations and death). Multivariate regression techniques were used to compare the risks of outcomes between vaccinated and unvaccinated persons while controlling for covariates and confounders. Results for data pooled over the 6 seasons demonstrated that influenza vaccination was associated with significant reductions in hospitalizations, outpatient visits, and death among the elderly. Similar findings were observed for low, intermediate, and high risk subgroups. Vaccination was also associated with cost savings. These findings are consistent with results from studies conducted in other countries and over other seasons and strongly support age-based recommendations for annual influenza vaccination for all persons ages 65 and over.
DOI: 10.1016/s0264-410x(99)00105-x
PubMed: 10471180
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Complications of influenza and benefits of vaccination.</title><author><name sortKey="Nichol, K L" sort="Nichol, K L" uniqKey="Nichol K" first="K L" last="Nichol">K L Nichol</name><affiliation wicri:level="2"><nlm:affiliation>Medicine Service (111), VA Medical Center, Minneapolis, MN 55417, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medicine Service (111), VA Medical Center, Minneapolis, MN 55417</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10471180</idno><idno type="pmid">10471180</idno><idno type="doi">10.1016/s0264-410x(99)00105-x</idno><idno type="wicri:Area/Main/Corpus">00676</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00676</idno><idno type="wicri:Area/Main/Curation">000676</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000676</idno><idno type="wicri:Area/Main/Exploration">000676</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Complications of influenza and benefits of vaccination.</title><author><name sortKey="Nichol, K L" sort="Nichol, K L" uniqKey="Nichol K" first="K L" last="Nichol">K L Nichol</name><affiliation wicri:level="2"><nlm:affiliation>Medicine Service (111), VA Medical Center, Minneapolis, MN 55417, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medicine Service (111), VA Medical Center, Minneapolis, MN 55417</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Argentina (epidemiology)</term><term>Female (MeSH)</term><term>Heart Diseases (etiology)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (complications)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (mortality)</term><term>Influenza, Human (prevention & control)</term><term>Kidney Diseases (etiology)</term><term>Lung Diseases (etiology)</term><term>Male (MeSH)</term><term>Manitoba (epidemiology)</term><term>Rheumatic Diseases (etiology)</term><term>Spain (epidemiology)</term><term>United Kingdom (epidemiology)</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Argentine (épidémiologie)</term><term>Cardiopathies (étiologie)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (complications)</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Maladies du rein (étiologie)</term><term>Maladies pulmonaires (étiologie)</term><term>Manitoba (épidémiologie)</term><term>Mâle (MeSH)</term><term>Rhumatismes (étiologie)</term><term>Royaume-Uni (épidémiologie)</term><term>Sujet âgé (MeSH)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>États-Unis (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Argentina</term><term>Influenza, Human</term><term>Manitoba</term><term>Spain</term><term>United Kingdom</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Heart Diseases</term><term>Kidney Diseases</term><term>Lung Diseases</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Grippe humaine</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Argentine</term><term>Espagne</term><term>Grippe humaine</term><term>Manitoba</term><term>Royaume-Uni</term><term>États-Unis</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Cardiopathies</term><term>Maladies du rein</term><term>Maladies pulmonaires</term><term>Rhumatismes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Uncertainty regarding the benefits of influenza vaccination may contribute to the underutilization of this vaccine. We have conducted serial cohort studies using the administrative data bases of a Twin Cities based managed care organization to assess the impact of disease and benefits of vaccination among the elderly. For the 6 seasons 1990-1991 through 1995-1996, there were more than 20,000 elderly members of the health plan included in each cohort. Data collected included information on baseline demographic and health characteristics, vaccination status and outcomes (hospitalizations and death). Multivariate regression techniques were used to compare the risks of outcomes between vaccinated and unvaccinated persons while controlling for covariates and confounders. Results for data pooled over the 6 seasons demonstrated that influenza vaccination was associated with significant reductions in hospitalizations, outpatient visits, and death among the elderly. Similar findings were observed for low, intermediate, and high risk subgroups. Vaccination was also associated with cost savings. These findings are consistent with results from studies conducted in other countries and over other seasons and strongly support age-based recommendations for annual influenza vaccination for all persons ages 65 and over.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10471180</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>17 Suppl 1</Volume><PubDate><Year>1999</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Complications of influenza and benefits of vaccination.</ArticleTitle><Pagination><MedlinePgn>S47-52</MedlinePgn></Pagination><Abstract><AbstractText>Uncertainty regarding the benefits of influenza vaccination may contribute to the underutilization of this vaccine. We have conducted serial cohort studies using the administrative data bases of a Twin Cities based managed care organization to assess the impact of disease and benefits of vaccination among the elderly. For the 6 seasons 1990-1991 through 1995-1996, there were more than 20,000 elderly members of the health plan included in each cohort. Data collected included information on baseline demographic and health characteristics, vaccination status and outcomes (hospitalizations and death). Multivariate regression techniques were used to compare the risks of outcomes between vaccinated and unvaccinated persons while controlling for covariates and confounders. Results for data pooled over the 6 seasons demonstrated that influenza vaccination was associated with significant reductions in hospitalizations, outpatient visits, and death among the elderly. Similar findings were observed for low, intermediate, and high risk subgroups. Vaccination was also associated with cost savings. These findings are consistent with results from studies conducted in other countries and over other seasons and strongly support age-based recommendations for annual influenza vaccination for all persons ages 65 and over.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nichol</LastName><ForeName>K L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Medicine Service (111), VA Medical Center, Minneapolis, MN 55417, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N">Argentina</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008350" MajorTopicYN="N">Manitoba</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>9</Month><Day>2</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>9</Month><Day>2</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10471180</ArticleId><ArticleId IdType="pii">S0264-410X(99)00105-X</ArticleId><ArticleId IdType="doi">10.1016/s0264-410x(99)00105-x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Minnesota</li></region></list><tree><country name="États-Unis"><region name="Minnesota"><name sortKey="Nichol, K L" sort="Nichol, K L" uniqKey="Nichol K" first="K L" last="Nichol">K L Nichol</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000681 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000681 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:10471180
|texte= Complications of influenza and benefits of vaccination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:10471180" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |